Different Symptoms Important to Kidney Cancer Patients and Clinicians

Published Jun 17, 2013
Chicago, IL, USA - The patient’s perspective is fast becoming an important component for health care decisions. For example, the Food and Drug Administration now has guidance for the development of patient-reported outcome instruments. Patients with advanced kidney cancer are most concerned about fatigue, treatment side effects, and worry about one’s condition getting worse. Kidney cancer physicians more readily focus on symptoms that suggest disease progression or factors that can reduce or delay treatment such as bone pain, fever, and weight loss. The NFKSI-19 symptom index demonstrated preliminary reliability and validity supporting its use in assessing health-related quality of life in clinical trials and routine clinical practice. Health-related quality of life is critical, particularly when curative treatment options are limited. Both the clinician and patient perspectives have been included in the article “Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer,” published in Value in Health. Nan Rothrock, PhD, author of the study states, “By utilizing both patient and clinician perspectives, we have a measure that addresses patients’ concerns about quality of life as well as symptoms that are critical for treatment planning.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×